AstraZeneca Says NEURO-TTRansform Phase III Trial Meets Co-primary Endpoints
EU Opens Investigation Into Possible Anticompetitive Disparagement By Vifor Pharma Of Iron Medicine
Sana : Data Shows Survival Of Transplanted Hypoimmune IPSC-Derived Differentiated Cell Types
Sandoz: EMA Accepts Application For Proposed Biosimilar Adalimumab's High Concentration Formulation
ObsEva: EC Grants Marketing Authorization For Yselty For Treatment Of Uterine Fibroids
Addex Ends Dipraglurant Phase 2b/3 Study For Dyskinesia Associated With Parkinson's Disease